Review of the economic evidence on the use of deep brain stimulation in late stage Parkinson's disease;Revisión de la evidencia económica sobre el uso de la estimulación cerebral profunda en la enfermedad de Parkinson avanzada

Neurologia

Volumn 24, Issue 4, 2009, Pages 220-229

  Puig Junoy, Jaume ^a   Puig Peiro R ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

Author keywords

Cost analysis; Deep brain stimulation; Economic evaluation; Parkinson's disease; Subthalamic stimulation

Indexed keywords

BRAIN DEPTH STIMULATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HUMAN; MEDLINE; PARKINSON DISEASE; PATIENT CARE; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; REVIEW; SYSTEMATIC REVIEW;

ANTIPARKINSON AGENTS; COST OF ILLNESS; COSTS AND COST ANALYSIS; DEEP BRAIN STIMULATION; HUMANS; PARKINSON DISEASE; SPAIN;

EID: 68049096089     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Costa C, Castiñera MC. Enfermedad de Parkinson. Guías Clínicas Fisterra (online). Disponible en http://www.fisterra.com/guias2/ parkinson.asp.
2. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurotherapeutics 2006;6:1403-1411 (Pubitemid 44696265)
3. D'Ausilio A, Marconi S, Antonini A, Tamma F, Valzania F, Berto P. Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase. Recenti Prog Med 2003;94:484-493
4. Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month tratement outcome. Mov Disord 2007;22:1145-1149 (Pubitemid 47067225)
5. Sydow O. Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion. FEBS Journal 2008. doi:10.1111/j.1742-4658.2008.06295.x.
6. Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Ardouin C, et al. Five-year follow-up of biltaeral stimulation of hte subthalamic nucleus in Avanced Parkinson's disease. N Engl J Med 2003;349:1925-1934 (Pubitemid 37409709)
7. Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995;345:91-95
8. Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, et al. Electrical stimulation of the subthalamic nucleus in Advanced Parkinson's disease. N Engl J Med 1998;339:1105-1111 (Pubitemid 28465758)
9. The Deep Brain Stimulation for Parkinson's Disease Study Group. Deep brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001;345:956-963
10. Molinnuevo JL, Valldeoriola F, Tolosa E, Rumia J, Valls-Sole J, Roldan H, et al. Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson's disease. Arch Neurol 2000;57:983-988 (Pubitemid 30452503)
11. Moro E, Scerrati M, Romito LMA, Roselli R, Tonali P, Albanese A. Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. Neurology 1999;53:85-90. (Pubitemid 29329653)
12. Vingerhoets FJG, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J. Subthalamic DBS replaces levodopa in Parkinson's disease. Neurology 2002; 58:396-401.
13. a ed. Madrid: Díaz de Santos, 2001.
14. Gold MR, Siegel JE, Russell LB, Weinstein MC, editores. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
15. Tomaszewski KJ, Holloway RG. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 2001;57:663-671 (Pubitemid 32782995)
16. Spottke EA, Volkmann J, Lorenz D, Krack P, Smala AM, Sturm V, et al. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 2002;249:759-766 (Pubitemid 34651759)
17. Gerzeli S, Cavallo MC, Caprari F, Ponzi P, Gruppo di Studio DBS. Analysis of deep brain stimulation (DBS) costs: an observational study on Italian patients. Pharmacoeconomics-Italian Research Articles 2002;4:66-79. (Pubitemid 35174236)
18. Charles PD, Padaliya BB, Newman AJ, Gill CE, Covington CD, Fang JY, et al. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat Disord 2004;10:475-479 (Pubitemid 39489880)
19. McIntosh E, Gray A, Aziz T. Estimating the costs of surgical innovations: the case for subthalamic nucleus stimulation in the treatment of advanced Parkinson's disease. Mov Disord 2003;18:993-999 (Pubitemid 37185206)
20. Meissner W, Schreiter D, Volkmann J, Trottenberg T, Schneider GH, Sturm V, et al. Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany. J Neurol 2005;252:218-223 (Pubitemid 40385598)
21. National Collaborating Centre for Chronic Conditions. Parkinson's Disease: national clinical guideline for diagnosis and management in primary and secondary care. Appendix F:187-193. London: Royal College of Physicians, 2006.
22. Fraix V, Houeto JL, Lagrange C, Le Pen C, Krystkowiak P, Guehl D, et al. SPARK Study Group. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:443-449
23. Valldeoriola F, Morsi O, Tolosa E, Rumià J, Martí MJ, Martínez-Martín P. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. Mov Disord 2007;22:2183-2191